Lurasidone
An N-arylpiperazine antipsychotic.
General information
Lurasidone is a second generation (atypical) antipsychotic drug. It is used for the treatment of schizophrenia and bipolar depression (LiverTox).
Lurasidone on DrugBank
Lurasidone on PubChem
Lurasidone on Wikipedia
Marketed as
LATUDA; LURASIDONE HYDROCHLORIDE
C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets
Small molecule In silico |
in silico | 2.03 | Predicted to bind multiple SARS-CoV-2 factors and to have favourable pharmacokinetic properties. |
Nov/15/2020 |
|
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
RdRpol Small molecule In vitro In silico |
in silico; Huh 7-hACE2 cells | 4.10 | Inhibited SARS-CoV-2 infection in a high content microscopy assay with an EC50 of ca. 18 μM and high selectivity (CC50 of ca. 118). The drug also displayed efficacy in a viral yield reduction assay with an estimated EC50 of >1000 μM. Based on computational modelling, the antiviral activity stems from RNA-dependent RNA polymerase inhibition. |
Mar/10/2021 |
